Lupin Leads US Competition On Risperdal Consta With CGT Exclusivity

Long-Acting Injectable Risperidone Will Benefit From 180-Day Award

 
• By Dave Wallace
  
Lupin’s three presentations have hit the mark, winning the firm a coveted 180 (Shutterstock)

More from Generics

More from Products